Gastric mucosa conditions during atrophic gastritis and gastric neuroendocrine neoplasia type 1 (gNEN 1)

#4154

Introduction: Worldwide frequency of neuroendocrine tumors increased, which is associated with improved approaches to the diagnosis of chronic diseases of the upper digestive tract. Management of these neoplasms in real clinical practice can be difficult.

Aim(s): To present the results of observation of patients with gNEN 1 on the background of systematic use of gastroprotective therapy.

Materials and methods: The research included 65 patients with gNEN 1 who were observed from 1 to 13 years. All of the patients had gastroprotective therapy in regime: rebamipide 100 mg, 3 times a day during 8 weeks three times a year. The dynamics of the disease after conservative treatment was measured using endoscopy data and the results of follow-up biopsy according to the OLGA (Operative Link on Gastritis Assessment) staging system.

Conference:

Presenting Author: Konyakhina A

Authors: Konyakhina A, Feidorov I, Salimgereeva D,

Keywords: gNEN, atrophic gastritis, OLGA, rebamipide,